Combining anti‐IgE with oral immunotherapy. Issue 7 (7th September 2017)

• Record Type: Journal Article
• Authors: Lin, Chunrong; Lee, Ivan T.; Sampath, Vanitha; Dinakar, Chitra; DeKruyff, Rosemarie H.; Schneider, Lynda C.; Nadeau, Kari Christine
• Is Part Of: Pediatric allergy and immunology. Volume 28:Issue 7(2017)
• Page Start: 619
• Page End: 627
• Publication Date: 2017-09-07
• Subjects: anaphylaxis -- anti‐IgE -- desensitization -- efficacy -- food allergy -- omalizumab -- oral immunotherapy -- safety -- tolerance; Allergy in children -- Periodicals; Immunologic diseases in children -- Periodicals; 617
• DOI: 10.1111/pai.12767
• Languages: English
• ISSNs: 0905-6157

Abstract

Abstract: Food allergy is a significant medical problem that affects up to 8% of children in developed countries. At present, there are no curative therapies available in routine practice and management of food allergy involves strict allergen avoidance, education, and prompt treatment upon accidental exposure. Oral immunotherapy (OIT) is an efficacious experimental approach to food allergy and has been shown to provide a substantial benefit in terms of allergen desensitization. However, OIT is associated with high rates of allergic reactions, and the period of protection offered by OIT appears to be limited and highly variable. Recurrence of allergen sensitivity after a period of treatment discontinuation is commonly observed. With the aim of overcoming these limitations of OIT, several trials have studied omalizumab (anti‐IgE monoclonal antibody) as an adjuvant treatment for patients undergoing OIT. Results from these trials have shown that the addition of omalizumab to OIT leads to a significant decrease in the frequency and severity of reactions, which allows for an increase in the threshold of tolerance to food allergens. This review provides a summary of the current literature and addresses some of the key questions that remain regarding the use of omalizumab in conjunction with OIT.